

Wednesday, 26. October 2022*Educational Sessions*

08:45 - 09:45

Room 2

Educational Session 1: Treatment of relapsing-remitting MS*Chair:* Emmanuelle Waubant, US**Introduction by chairs**

08:45 - 08:50

How to treat MS patients with concomitant other autoimmune diseases?

08:50 - 09:05

How to define treatment failure?

09:05 - 09:20

Speaker: Emmanuelle Waubant, US**Should RIS patients be treated?**

09:20 - 09:35

Speaker: Christine Lebrun-Frenay, FR**Discussion**

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 3

Educational Session 2: Infections and Vaccinations in MS*Chair:* Sandra Vukusic, FR*Chair:* Bernhard Hemmer, DE**Introduction by chairs**

08:45 - 08:50

Infections as trigger, prodrome or consequence of MS

08:50 - 09:05

Speaker: Chiara Zecca, CH**Is there a risk for MS patients to get vaccinated?**

09:05 - 09:20

Speaker: Bernhard Hemmer, DE**Who should be vaccinated with what and when?**

09:20 - 09:35

Speaker: Sandra Vukusic, FR**Discussion**

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 4

Educational Session 3: Early stages of MS*Chair:* Ruth Ann Marrie, CA*Chair:* Darin Okuda, US**Introduction by chairs**

08:45 - 08:50

When the disease starts? MS Prodrome

08:50 - 09:05

Speaker: Ruth Ann Marrie, CA**The radiological isolated syndrome (RIS), is it already MS?**

09:05 - 09:20

Speaker: Darin Okuda, US**How paediatric MS could shed light on early MS?**

09:20 - 09:35

Speaker: Yael Hacoheh, GB

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 5

Educational Sessions 4 (RIMS): Updates in MS rehabilitation - cognitive and physical functioning and fatigue management

Chair: Anders Guldhammer Skjerbaek, DK

Chair: Roshan das Nair, GB

Introduction by chairs

08:45 - 08:50

Cognitive rehabilitation

08:50 - 09:05

Speaker: Roshan das Nair, GB

Optimizing physical functioning

09:05 - 09:20

Speaker: Anders Guldhammer Skjerbaek, DK

Fatigue management in rehabilitation

09:20 - 09:35

Speaker: Daphne Kos, BE

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 6

Educational Session 5: Pathology of MS

Chair: Inge Huitinga, NL

Chair: Hans Lassmann, AT

Introduction by chairs

08:45 - 08:50

Inflammatory reaction within the CNS of multiple sclerosis patients: mechanisms and potential triggers

08:50 - 09:05

Speaker: Inge Huitinga, NL

Tracking the origin of neurodegeneration

09:05 - 09:20

Speaker: Doron Merkler, CH

The pathology of multiple sclerosis and MOG antibody associated inflammatory demyelinating disease: similarities and differences

09:20 - 09:35

Speaker: Hans Lassmann, AT

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 7

Educational Sessions 6 (MAGNIMS): MRI and the diagnosis of MS - where we are and what the future is

Chair: Jaume Sastre-Garriga, ES

Chair: Olga Ciccarelli, GB

Introduction by chairs

08:45 - 08:50

The 2017 McDonald criteria: a critical reappraisal	08:50 - 09:05
<i>Speaker:</i> Jaume Sastre-Garriga, ES	
Future MRI measures (optic nerve MRI, central vein sign, cortical lesions, leptomeningeal enhancement)	09:05 - 09:20
<i>Speaker:</i> Olga Ciccarelli, GB	
MS mimics: red and green flags	09:20 - 09:35
<i>Speaker:</i> Frederik Barkhof, NL	
Discussion	09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 8

Educational Session 7: Life style and environmental factors*Chair:* Ellen Mowry, US*Chair:* Tomas Olsson, SE

Introduction by chairs	08:45 - 08:50
Genes and environment in MS	08:50 - 09:05
<i>Speaker:</i> Tomas Olsson, SE	
Dietary inflammatory index and MS; action needed?	09:05 - 09:20
<i>Speaker:</i> Ellen Mowry, US	
Role of gut microbiota and susceptibility of MS	09:20 - 09:35
<i>Speaker:</i> Anne-Katrin Pröbstel, CH	
Discussion	09:35 - 09:45

10:00 - 11:00

Room 1

European Charcot Foundation Symposium: The patient at the centre: role of patient reported outcomes*Chair:* Maria Pia Amato, IT*Chair:* Giancarlo Comi, IT

Introduction	10:00 - 10:05
<i>Speaker:</i> Helga Weiland, ZA	
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: progresses and open questions	10:05 - 10:20
<i>Speaker:</i> Paola Zaratin, IT	
e-health to capture “patient voice”	10:20 - 10:35
<i>Speaker:</i> Letizia Leocani, IT	
Is time to consider PROs in decision processes for health care systems?	10:35 - 10:50
<i>Speaker:</i> Usman Khan, US	
Discussion	10:50 - 11:00

Therapy / Global views

10:00 - 11:00

Room 2

Hot Topic 1: High efficacy therapies*Chair:* Patricia Coyle, US*Chair:* Jop Mostert, NL

Introduction by chairs	10:00 - 10:05
Early predictors of treatment outcome	10:05 - 10:15
<i>Speaker:</i> Xavier Montalban, ES	
How to timely switch to high efficacy DMT	10:15 - 10:25
<i>Speaker:</i> Dalia L. Rotstein, CA	
Flipping the pyramid and beyond	10:25 - 10:35
<i>Speaker:</i> Gavin Giovannoni, GB	
Discussion	10:35 - 11:00

Clinical

10:00 - 11:00

Room 3

Hot Topic 2: NMO-SD*Chair:* Kazuo Fujihara, JP*Chair:* Sandra Vukusic, FR

Introduction by chairs	10:00 - 10:05
Aligning 'new' and 'old' treatments for NMO-SD	10:05 - 10:15
<i>Speaker:</i> Jacqueline Palace, GB	
The immunology of NMO-SD and MOG-AD	10:15 - 10:25
<i>Speaker:</i> Marvin van Luijn, NL	
Stopping or de-escalating immune suppressive treatments in NMO-SD and MOG-AD	10:25 - 10:35
<i>Speaker:</i> Romain Marignier, FR	
Discussion	10:35 - 11:00

Imaging and non-imaging biomarkers/Translational

10:00 - 11:00

Room 4

Hot Topic 3: Novel body fluid biomarkers*Chair:* Claire Bridel, CH*Chair:* Tanuja Chitnis, US

Introduction by chairs	10:00 - 10:05
Emerging CSF biomarkers	10:05 - 10:15
<i>Speaker:</i> Bibiana Bielekova, US	
Emerging blood biomarkers	10:15 - 10:25
<i>Speaker:</i> Charlotte Teunissen, NL	
Novel fluid biomarkers for progressive MS	10:25 - 10:35
<i>Speaker:</i> Nicolás Fissolo, ES	

Discussion	10:35 - 11:00
<i>Pathogenesis</i> 10:00 - 11:00	Room 5
Hot Topic 4: New ways of imaging MS pathology	
<i>Chair:</i> Inge Huitinga, NL	
<i>Chair:</i> Patrick Vermersch, FR	
Introduction by chairs	10:00 - 10:05
Single nucleus sequencing of MS lesions -role of microglia	10:05 - 10:15
<i>Speaker:</i> Bart Eggen, NL	
Multiplex imaging of MS lesions	10:15 - 10:25
<i>Speaker:</i> Valeria Ramaglia, CA	
Microglia-astrocyte communication in CNS inflammation	10:25 - 10:35
<i>Speaker:</i> Francisco Quintana, US	
Discussion	10:35 - 11:00
10:00 - 11:00	Room 6
Free Communications 1: Neurobiology of MS	
<i>Chair:</i> Marcin Mycko, PL	
Introduction by chairs	10:00 - 10:05
Discussion	10:05 - 10:25
<i>Educational Sessions</i> 10:00 - 11:00	Room 7
Educational Session 8 (MAGNIMS): MRI and the prognosis of MS - where we are and what the future is	
<i>Chair:</i> Maria Assunta Rocca, IT	
<i>Chair:</i> Claudio Gasperini, IT	
Introduction by chairs	10:00 - 10:05
The use of MRI in assessing prognosis – What are the clinician’s needs?	10:05 - 10:20
<i>Speaker:</i> Claudio Gasperini, IT	
Conventional MRI in MS prognosis.	10:20 - 10:35
<i>Speaker:</i> Nicola De Stefano, IT	
Non-conventional MRI in MS prognosis	10:35 - 10:50
<i>Speaker:</i> Maria Assunta Rocca, IT	
Discussion	10:50 - 11:00
<i>Nurses Sessions</i> 10:00 - 11:00	Room 8
Nurses' Session 1: MS treatment and research: the evolving role of the nurse	

Future perspectives of MS nursing from a neurologist view	10:00 - 10:00
MS treatment and the evolving role of the nurse	10:00 - 10:00
Research in MS nursing practice	10:00 - 10:00
<i>Break</i> 11:00 - 11:30	Room 1
Coffee Break	
<i>Plenary Sessions</i> 11:30 - 12:30	Room 1
Plenary Session 1: Welcome Addresses and ECTRIMS Lecture	
<i>Chair:</i> Maria Pia Amato, IT	
<i>Chair:</i> Mar Tintoré, ES	
<i>Chair:</i> Bernard Uitdehaag, NL	
Welcome to ECTRIMS 2022	11:30 - 12:00
<i>Speaker:</i> Maria Pia Amato, IT	
<i>Speaker:</i> Mar Tintoré, ES	
<i>Speaker:</i> Bernard Uitdehaag, NL	
ECTRIMS Lecture: Putting POMS in perspective	12:00 - 12:30
<i>Speaker:</i> Brenda Banwell, US	
<i>Break</i> 12:30 - 13:15	Room 1
Lunch Break	
<i>Satellite Symposium</i> 13:15 - 14:15	Room 1
Satellite Symposium 1	
<i>Satellite Symposium</i> 13:15 - 14:15	Room 2
Satellite Symposium 2	
<i>Therapy / Global views</i> 14:30 - 16:00	Room 1
Scientific Session 1: Personalised treatment	
<i>Chair:</i> Finn Sellebjerg, DK	
<i>Chair:</i> Eva Kubala Havrdová, CZ	
Introduction by chairs	14:30 - 14:35
When to start which DMT in whom?	14:35 - 14:50
<i>Speaker:</i> Jaume Sastre-Garriga, ES	
Personalized dosing of NTZ and OCR	14:50 - 15:05
<i>Speaker:</i> Zoé van Kempen, NL	
Platform presentations of related original papers	15:05 - 15:05

Discussion	15:05 - 15:32
<i>Pathogenesis</i> 14:30 - 16:00	Room 2
Scientific Session 2: Remyelination	
Introduction by chairs	14:30 - 14:35
Imaging de- and remyelination <i>Speaker:</i> Cristina Granziera, CH	14:35 - 14:50
Towards promoting remyelination in clinic <i>Speaker:</i> Catherine Lubetzki, FR	14:50 - 15:05
Platform presentations of related original papers	15:05 - 15:05
Discussion	15:05 - 15:32
<i>Imaging and non-imaging biomarkers/Translational</i> 14:30 - 16:00	Room 3
Scientific Session 3: A network disease	
<i>Chair:</i> Aurélie Ruet, FR	
Introduction by chairs	14:30 - 14:35
Current concepts in network neuroscience <i>Speaker:</i> Lucina Qazi Uddin, US	14:35 - 14:50
The network collapse and clinical progression <i>Speaker:</i> Menno M. Schoonheim, NL	14:50 - 15:05
Platform presentations of related original papers	15:05 - 15:05
Discussion	15:05 - 15:32
<i>Imaging and non-imaging biomarkers/Translational</i> 14:30 - 16:00	Room 4
Scientific Session 4: Novel modelling approaches	
<i>Chair:</i> Marco Battaglini, IT	
<i>Chair:</i> Hugo Vrenken, NL	
Introduction by chairs	14:30 - 14:35
Machine learning: What have we learnt? <i>Speaker:</i> Kerstin Ritter, DE	14:35 - 14:50
Clinical prediction using complex models <i>Speaker:</i> Arman Eshaghi, GB	14:50 - 15:05
Platform presentations of related original papers	15:05 - 15:05
Discussion	15:05 - 15:32

14:30 - 15:30 Room 5

Free Communications 2: Pregnancy

Introduction by chairs 14:30 - 14:35

Discussion 14:35 - 14:55

Young Scientific Investigators' Session

14:30 - 15:30

Room 6

Young Scientific Investigators' Session 1: Immune profiling

Chair: Franziska Di Pauli, AT

Chair: Kjell-Morten Myhr, NO

Introduction by chairs 14:30 - 14:35

Discussion 14:35 - 14:55

Educational Sessions

14:30 - 15:30

Room 7

Educational Session 9: Special situations in neuroimmunology care - pregnancy, comorbidity, elderlies

Chair: Melinda Magyari, DK

Chair: Zsolt Illes, DK

Introduction by chairs 14:30 - 14:35

Pregnancy planning in MS and NMOSD: consider the differences related to child, mother and treatments 14:35 - 14:50

Speaker: Melinda Magyari, DK

Comorbidities in neuroimmunological diseases: consider age, treatment interactions and comorbidities (including autoimmune diseases) in MS, NMOSD 14:50 - 15:05

Speaker: Helen Tremlett, CA

The elderlies: how immunosenescence and inflammaging contribute to risk consideration, differential diagnostic concerns, treatment choices and potential de-escalation in neuroimmunology 15:05 - 15:20

Speaker: Zsolt Illes, DK

Discussion 15:20 - 15:30

Nurses Sessions

14:30 - 15:30

Room 8

Nurses' Session 2

Break

16:00 - 16:30

Room 1

Coffee Break

Poster Session

16:30 - 18:30

Room 1

Poster Session 1

Satellite Symposium

17:30 - 18:30

Room 1

Satellite Symposium 3

Satellite Symposium

17:30 - 18:30

Room 2

Satellite Symposium 4

Thursday, 27. October 2022

Satellite Symposium
08:45 - 09:45

Room 1

Satellite Symposium 5

Satellite Symposium
08:45 - 09:45

Room 2

Satellite Symposium 6

Therapy / Global views
10:00 - 11:00

Room 1

Hot Topic 5: Escalating and de-escalating DMTs

Chair: Maria Trojano, IT

Chair: Joep Killestein, NL

Introduction by chairs	10:00 - 10:05
Treating active MS following induction therapies	10:05 - 10:15
<i>Speaker:</i> Gilles Edan, FR	
Long-term stable MS on high-efficacy therapies	10:15 - 10:25
<i>Speaker:</i> Emmanuelle Waubant, US	
Long-term stable MS on platform therapies	10:25 - 10:35
<i>Speaker:</i> Eva Strijbis, NL	
Discussion	10:35 - 11:00

Imaging and non-imaging biomarkers/Translational
10:00 - 11:00

Room 2

Hot Topic 6: Inclusion of optic nerve lesions in McDonald criteria

Chair: Olivier Outteryck, FR

Chair: Peter Calabresi, US

Introduction by chairs	10:00 - 10:05
Rationale and detection by MRI	10:05 - 10:15
<i>Speaker:</i> Frederik Barkhof, NL	
Clinical implementation	10:15 - 10:25
<i>Speaker:</i> Angela Vidal-Jordana, ES	
Non-MRI assessment of optic nerve lesions	10:25 - 10:35
<i>Speaker:</i> Laura Balcer, US	
Discussion	10:35 - 11:00

10:00 - 11:00

Room 3

Burning Debate: Presymptomatic MS or radiologically-isolated syndrome (RIS) should be actively monitored and treated

Chair: Barbara Willekens, BE

Introduction by chair	10:00 - 10:05
Yes	10:05 - 10:20
<i>Speaker:</i> Christine Lebrun-Frenay, FR	
No	10:20 - 10:35
<i>Speaker:</i> Ide Smets, NL	
Discussion	10:35 - 11:00
<i>Therapy / Global views</i> 10:00 - 11:00	Room 4
Hot Topic 7: Lifestyle interventions	
<i>Chair:</i> Leo Visser, NL	
<i>Chair:</i> Robert Motl, US	
Introduction by chairs	10:00 - 10:05
Exercise	10:05 - 10:15
<i>Speaker:</i> Ulrik Dalgas, DK	
Diet	10:15 - 10:25
<i>Speaker:</i> Brigit de Jong, NL	
Smoking, stress and sleep	10:25 - 10:35
<i>Speaker:</i> Christoph Heesen, DE	
Discussion	10:35 - 11:00
10:00 - 11:00	Room 5
Free Communications 3: NMOSD	
Introduction by chairs	10:00 - 10:05
Discussion	10:05 - 10:25
<i>Therapy / Global views</i> 10:00 - 11:00	Room 6
Meet the Expert 1: Pregnancy and breastfeeding in MS	
<i>Chair:</i> Rhonda Voskuhl, US	
<i>Chair:</i> Elisabeth G Celius, NO	
10:00 - 11:00	Room 7
Free Communications 4: Diagnostic and prognostic biomarkers	
Introduction by chairs	10:00 - 10:05
Discussion	10:05 - 10:25

Educational Sessions

10:00 - 11:00

Room 8

Educational Session 10 (RIMS): Updates in MS rehabilitation: speech and swallowing, bladder and bowel management and sexual health*Chair:* Turhan Kahraman, TR*Chair:* Leena Maria Heikkola, FI

Introduction by chairs	10:00 - 10:05
Bladder and bowel management: rehabilitation approaches	10:05 - 10:20
<i>Speaker:</i> Turhan Kahraman, TR	
Sexual health and psychological wellbeing	10:20 - 10:35
<i>Speaker:</i> Jana Pöttgen, DE	
Optimizing speech and swallowing	10:35 - 10:50
<i>Speaker:</i> Leena Maria Heikkola, FI	
Discussion	10:50 - 11:00

Break

11:00 - 11:30

Room 1

Coffee Break*Clinical*

11:30 - 13:00

Room 1

Scientific Session 5: Progressive MS*Chair:* Kathy Smith, US*Chair:* Jan Meilof, NL

Introduction by chairs	11:30 - 11:35
Outcome measures in progressive MS trials	11:35 - 11:50
<i>Speaker:</i> Ruth Ann Marrie, CA	
Clinical trial design in progressive MS	11:50 - 12:05
<i>Speaker:</i> Maria Pia Sormani, IT	
Platform presentations of related original papers	12:05 - 12:05
Discussion	12:05 - 12:32

Clinical

11:30 - 13:00

Room 2

Scientific Session 6: Treating children with MS ('Rogier Hintzen session')*Chair:* Evangeline Wassmer, GB*Chair:* Yael Hacoheh, GB

Introduction by chairs	11:30 - 11:35
Management of the clinical consequences of a child with MS	11:35 - 11:50
<i>Speaker:</i> E. Ann Yeh, CA	
Why Immunomodulatory treatment is different in children with MS	11:50 - 12:05

	<i>Speaker:</i> Kevin Rostasy, DE	
	Platform presentations of related original papers	12:05 - 12:05
	Discussion	12:05 - 12:32
<i>Clinical</i>		
11:30 - 13:00		Room 3
Scientific Session 7: Advanced mobility assessment		
<i>Chair:</i> Mary Galea, AU		
<i>Chair:</i> Johanna Jonsdottir, IT		
	Introduction by chairs	11:30 - 11:35
	Wearable technology	11:35 - 11:50
	<i>Speaker:</i> Andrea Tacchino, IT	
	3D gait analysis	11:50 - 12:05
	<i>Speaker:</i> Vincent de Groot, NL	
	Platform presentations of related original papers	12:05 - 12:05
	Discussion	12:05 - 12:32
<i>Pathogenesis</i>		
11:30 - 13:00		Room 4
Scientific Session 8: Immune cell trafficking into the CNS		
<i>Chair:</i> Britta Engelhardt, CH		
<i>Chair:</i> Jack Van Horssen, NL		
	Introduction by chairs	11:30 - 11:35
	Immune cell trafficking across brain barriers	11:35 - 11:50
	<i>Speaker:</i> Alexandre Prat, CA	
	Functional characterisation of the dural sinuses as a neuroimmune interface	11:50 - 12:05
	<i>Speaker:</i> Jonathan Kipnis, US	
	Platform presentations of related original papers	12:05 - 12:05
	Discussion	12:05 - 12:32
<i>Therapy / Global views</i>		
11:30 - 13:00		Room 5
Scientific Session RIMS 1: Aging and MS: impact of age on MS rehabilitation		
<i>Chair:</i> Letizia Leocani, IT		
<i>Chair:</i> Piet Leopold Eelen, BE		
	The impact of age in relation to disabilities and key symptoms in MS and other neurological diseases	11:30 - 11:45
	<i>Speaker:</i> Lars G Hvid, DK	
	Rehabilitation in MS across the life span	11:45 - 12:00

Speaker: Marcia Finlayson, CA

Platform presentations	12:00 - 12:00
Presentation 1	12:00 - 12:07
Presentation 2	12:07 - 12:14
Presentation 3	12:14 - 12:21
Presentation 4	12:21 - 12:28
Discussion	12:28 - 12:55

Therapy / Global views

11:30 - 12:30

Room 6

Meet the Expert 2: Choosing therapy - similar compounds, same effect?

Chair: Ludwig Kappos, CH

Chair: Stephen Hauser, US

Pathogenesis

11:30 - 12:30

Room 7

Young Scientific Investigators' Session 2: Cellular profiling

Chair: Marie D'hooghe, BE

Chair: Christian Philipp Kamm, CH

Introduction by chairs	11:30 - 11:35
Discussion	11:35 - 11:55

Educational Sessions

11:30 - 12:30

Room 8

Educational Session 11: A "Surface-in" gradient of brain and spinal cord damage in MS - pathophysiology and clinical relevance

Chair: Bruno Stankoff, FR

Chair: Roberta Magliozzi, IT

Introduction by chairs	11:30 - 11:35
Regionalisation of tissue damage on MRI	11:35 - 11:50
<i>Speaker:</i> Declan Chard, GB	
Mechanisms of the surface-in gradient: insight from molecular imaging	11:50 - 12:05
<i>Speaker:</i> Bruno Stankoff, FR	
Biological substrate of the surface-in gradient : lessons from pathology	12:05 - 12:20
<i>Speaker:</i> Roberta Magliozzi, IT	
Discussion	12:20 - 12:30

Break

13:00 - 13:45

Room 1

Lunch Break*Satellite Symposium*

13:45 - 14:45

Room 1

Satellite Symposium 7*Satellite Symposium*

13:45 - 14:45

Room 2

Satellite Symposium 8*Imaging and non-imaging biomarkers/Translational*

15:00 - 16:30

Room 1

Scientific Session 9 MRI: Updated MAGNIMS-NAIMS-CMSC guidelines*Chair:* Daniel Ontaneda, US*Chair:* Maria Assunta Rocca, IT**Introduction by chairs**

15:00 - 15:05

Use in diagnosis, prognosis and safety monitoring

15:05 - 15:20

Speaker: Alex Rovira, ES**Dissemination and implementation strategy**

15:20 - 15:35

Speaker: David Li, CA**Platform presentations of related original papers**

15:35 - 15:35

Discussion

15:35 - 16:02

Pathogenesis

15:00 - 16:30

Room 2

Scientific Session 10: B and T cells*Chair:* Joost Smolders, NL*Chair:* Frauke Zipp, DE**Introduction by chairs**

15:00 - 15:05

B-cell trafficking

15:05 - 15:20

Speaker: Jennifer Gommerman, CA**Novel insights in circulating B and T cells in MS**

15:20 - 15:35

Speaker: Klaus Dornmair, DE**Platform presentations of related original papers**

15:35 - 15:35

Discussion

15:35 - 16:02

Clinical

15:00 - 16:30

Room 3

Scientific Session 11: Quality of life*Chair:* Iris-Katharina Penner, CH*Chair:* Karin van der Hiele, NL

Introduction by chairs	15:00 - 15:05
Treating psychological factors	15:05 - 15:20
<i>Speaker:</i> Victoria Leavitt, US	
Mechanisms underlying fatigue	15:20 - 15:35
<i>Speaker:</i> Federica Picariello, GB	
Platform presentations of related original papers	15:35 - 15:35
Discussion	15:35 - 16:02
<i>Pathogenesis</i> 15:00 - 16:30	Room 4
Scientific Session 12: The earliest events in MS	
<i>Chair:</i> Jeroen Geurts, NL	
<i>Chair:</i> Luke Healy, CA	
Introduction by chairs	15:00 - 15:05
Earliest inflammatory changes	15:05 - 15:20
<i>Speaker:</i> Richard Reynolds, GB	
MS as an inside-out pathology	15:20 - 15:35
<i>Speaker:</i> Peter Stys, CA	
Platform presentations of related original papers	15:35 - 15:35
Discussion	15:35 - 16:02
<i>Therapy / Global views</i> 15:00 - 16:30	Room 5
Scientific Session RIMS 2: Innovations in MS: Technology-supported rehabilitation	
<i>Chair:</i> Giampaolo Brichetto, IT	
<i>Chair:</i> Jana Pöttgen, DE	
Innovations in technology for rehabilitation	15:00 - 15:15
<i>Speaker:</i> Peter Feys, BE	
Internet-based technology use in daily life	15:15 - 15:30
<i>Speaker:</i> Yael Goverover, US	
Discussion	15:30 - 15:57
15:00 - 16:00	Room 6
Free Communications 5: Treatment	
<i>Clinical</i> 15:00 - 16:00	Room 7
Young Scientific Investigators' Session 3: Long-term outcomes and safety	
<i>Chair:</i> Bob van Oosten, NL	
<i>Chair:</i> Carmen Tur, ES	
Introduction by chairs	15:00 - 15:05

Discussion	15:05 - 15:25
<i>Educational Sessions</i> 15:00 - 16:00	Room 8
Educational Session 12: Cognitive impairment in MS - an update <i>Chair:</i> Laura Hancock, US <i>Chair:</i> Bruno Brochet, FR	
Introduction by chairs	15:00 - 15:05
Diagnosis and diagnostic challenges <i>Speaker:</i> Laura Hancock, US	15:05 - 15:20
Underlying Mechanisms <i>Speaker:</i> Menno M. Schoonheim, NL	15:20 - 15:35
Treatment: what is new? <i>Speaker:</i> Bruno Brochet, FR	15:35 - 15:50
Discussion	15:50 - 16:00
<i>Break</i> 16:30 - 17:00	Room 1
Coffee Break	
<i>Poster Session</i> 17:00 - 19:00	Room 1
Poster Session 2	
<i>Satellite Symposium</i> 18:00 - 19:00	Room 1
Satellite Symposium 9	
<i>Satellite Symposium</i> 18:00 - 19:00	Room 2
Satellite Symposium 10	

Friday, 28. October 2022*Educational Sessions*

08:45 - 09:45

Room 2

Educational Session 13: Covid in MS*Chair:* Hans-Peter Hartung, DE*Chair:* Krzysztof Selmaj, PL

Introduction by chairs	08:45 - 08:50
Neurological symptoms and management of acute Covid infection in MS patients	08:50 - 09:05
<i>Speaker:</i> Krzysztof Selmaj, PL	
Post-Covid neurological symptoms	09:05 - 09:20
<i>Speaker:</i> Hans-Peter Hartung, DE	
Covid-induced cognitive residual impairment	09:20 - 09:35
<i>Speaker:</i> Maria Pia Amato, IT	
Discussion	09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 3

Educational Session 14: Treating NMOSD and MOGAD*Chair:* Jacqueline Palace, GB*Chair:* Kazuo Fujihara, JP

Introduction by chairs	08:45 - 08:50
How and when to treat AQP4-IgG-positive NMOSD	08:50 - 09:05
<i>Speaker:</i> Kazuo Fujihara, JP	
Treatment approach of antibody negative NMOSD	09:05 - 09:20
<i>Speaker:</i> Jacqueline Palace, GB	
MOGAD: its clinical course, MOG-IgG status and therapeutic evidence	09:20 - 09:35
<i>Speaker:</i> Romain Marignier, FR	
Discussion	09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 4

Educational Session 15: (Micro)-organisms and MS pathogenesis*Chair:* Alberto Ascherio, US*Chair:* Lisa Osborne, CA

Introduction by chairs	08:45 - 08:50
EBV, how does it increase the risk of MS?	08:50 - 09:05
<i>Speaker:</i> Alberto Ascherio, US	
HERV and the connection with MS	09:05 - 09:20

Speaker: Patrick Küry, DE

Helminths still alive as a MS treatment?

09:20 - 09:35

Speaker: Lisa Osborne, CA

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 5

Educational Session 16: Biomarkers in MS - from theory to clinical application

Chair: Fredrik Piehl, SE

Chair: Philip De Jager, US

Introduction by chairs

08:45 - 08:50

NfL and other blood biomarkers:

08:50 - 09:05

Speaker: Fredrik Piehl, SE

Immunoglobulin and other inflammatory markers in the CSF in MS

09:05 - 09:20

Speaker: Luisa María Villar, ES

CSF cell profiling in MS: methodology and promises

09:20 - 09:35

Speaker: Philip De Jager, US

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 6

Educational Session 17: Diagnosis of MS

Chair: Mar Tintoré, ES

Chair: Thomas Berger, AT

Introduction by chairs

08:45 - 08:50

Typical clinical MS presentations and possible pitfalls in the diagnosis

08:50 - 09:05

Speaker: Thomas Berger, AT

Atypical clinical syndromes: Diagnostic approach to the right diagnosis

09:05 - 09:20

Speaker: Mar Tintoré, ES

Early identification of secondary progressive MS

09:20 - 09:35

Speaker: Jiwon Oh, CA

Discussion

09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 7

Educational Session 18: Next generation neuroimmunology - how new technologies and novel approaches help to understand inflammatory chronic and demyelinating brain disorders in humans

Chair: Frauke Zipp, DE

Chair: Heinz Wiendl, DE

Introduction by chairs	08:45 - 08:50
A primer to use big(ger) data from clinical cohorts and its integration with novel modalities (machine learning continued) <i>Speaker:</i> Sergio E. Baranzini, US	08:50 - 09:05
Disease monitoring modalities and how they can inform about neuroinflammatory disease endophenotypes <i>Speaker:</i> Frauke Zipp, DE	09:05 - 09:20
How novel technologies can instruct about disease endophenotypes and disease-related compartments <i>Speaker:</i> Heinz Wiendl, DE	09:20 - 09:35
Discussion	09:35 - 09:45

Educational Sessions

08:45 - 09:45

Room 8

Educational Session 19: Latest updates in management of childbearing in women with MS and NMOSD*Chair:* Kerstin Hellwig, DE*Chair:* Riley Bove, US

Introduction by chairs	08:45 - 08:50
Pre-conception care for women with MS and NMOSD: contraception, pregnancy planning, fertility <i>Speaker:</i> Maria K. Houtchens, US	08:50 - 09:05
Pharmacological safety during pregnancy and lactation <i>Speaker:</i> Kerstin Hellwig, DE	09:05 - 09:20
Care for women with MS and NMOSD in the postpartum period <i>Speaker:</i> Riley Bove, US	09:20 - 09:35
Discussion	09:35 - 09:45

Clinical

10:00 - 11:30

Room 1

Scientific Session 13: COVID-19 and MS*Chair:* Olga Ciccarelli, GB*Chair:* Helmut Butzkueven, AU

Introduction by chairs	10:00 - 10:05
Looking back, what have we learnt? <i>Speaker:</i> Celine Louapre, FR	10:05 - 10:20
COVID-19: vaccination in MS patients <i>Speaker:</i> Anat Achiron, IL	10:20 - 10:35
Platform presentations of related original papers	10:35 - 10:35
Discussion	10:35 - 11:02

Clinical

10:00 - 11:30

Room 2

Scientific Session 14: e-Health*Chair:* Letizia Leocani, IT*Chair:* Paul Matthews, GB

Introduction by chairs	10:00 - 10:05
e-Health assessments	10:05 - 10:20
<i>Speaker:</i> Riley Bove, US	
e-Health interventions	10:20 - 10:35
<i>Speaker:</i> Tjalf Ziemssen, DE	
Platform presentations of related original papers	10:35 - 10:35
Discussion	10:35 - 11:02

10:00 - 11:30

Room 3

Scientific Session 15: Global views: Health care access around the globe*Chair:* Mohammad Ali Sahraian, IR*Chair:* Alexey Boyko, RU

Introduction by chairs	10:00 - 10:05
ECTRIMS: Access to high quality MS healthcare principles	10:05 - 10:15
<i>Speaker:</i> Maria Pia Amato, IT	
LACTRIMS: Barriers to the Accessibility and Continuity of Health-Care Services in People with Multiple Sclerosis	10:15 - 10:25
<i>Speaker:</i> Lorna Galleguillos, CL	
BCTRIMS: Impact of the Covid 19 pandemic on healthcare access for people with MS	10:25 - 10:35
<i>Speaker:</i> Milena Sales Pitombeira, BR	
MENACTRIMS: The role of E health technology: opportunities and challenges	10:35 - 10:45
<i>Speaker:</i> Reem Al Bunyan, SA	
PACTRIMS: Improving care coordination and responsiveness to patients' needs: the power of global collaboration	10:45 - 10:55
<i>Speaker:</i> Shanthi Viswanathan, MY	
ACTRIMS: Future perspectives and actions needed	10:55 - 11:05
<i>Speaker:</i> Emmanuelle Waubant, US	
Discussion	11:05 - 11:30

Therapy / Global views

10:00 - 11:30

Room 4

Scientific Session RIMS 3: People with MS at work: the role of vocational rehabilitation*Chair:* Roshan das Nair, GB*Chair:* Daphne Kos, BE

Optimizing employment and preventing job loss	10:00 - 10:15
<i>Speaker:</i> Kate Radford, GB	
Vocational rehabilitation interventions: lessons for MS from other health conditions	10:15 - 10:30
<i>Speaker:</i> Sverker Johansson, SE	
Presentation 1 tba	10:30 - 10:37
Presentation 2 tba	10:37 - 10:44
Presentation 3 tba	10:44 - 10:51
Presentation 4 tba	10:51 - 10:58
Discussion	10:58 - 11:25
<i>Clinical</i> 10:00 - 11:00	Room 5
Hot Topic 8: Pediatric MOGAD	
<i>Chair:</i> Silvia Tenembaum, AR	
<i>Chair:</i> Kumaran Deiva, FR	
Introduction by chairs	10:00 - 10:05
Classification of pediatric MOGAD	10:05 - 10:15
<i>Speaker:</i> Giulia Fadda, US	
Imaging and biomarkers in pediatric MOGAD	10:15 - 10:25
<i>Speaker:</i> Thais Armangue, ES	
Treatment of pediatric MOGAD	10:25 - 10:35
<i>Speaker:</i> Rinze Neuteboom, NL	
Discussion	10:35 - 11:00
<i>Clinical</i> 10:00 - 11:00	Room 6
Meet the Expert 3 Aging: impact on diagnosis and treatment	
<i>Chair:</i> Alan Thompson, GB	
<i>Chair:</i> Bianca Weinstock-Guttman, US	
10:00 - 11:00	Room 7
Free Communications 6: Imaging	
Introduction by chairs	10:00 - 10:05
Discussion	10:05 - 10:25

Educational Sessions

10:00 - 11:00

Room 8

Educational Session 20: Approaches to alternative treatment algorithms*Chair:* Eva Strijbis, NL*Chair:* Joep Killestein, NL

Introduction by chairs	10:00 - 10:05
Biosimilars and off-label therapies	10:05 - 10:20
<i>Speaker:</i> Bob van Oosten, NL	
When to stop disease modifying therapy	10:20 - 10:35
<i>Speaker:</i> Eva Strijbis, NL	
Personalised and extended dosing of monoclonal antibodies	10:35 - 10:50
<i>Speaker:</i> Joep Killestein, NL	
Discussion	10:50 - 11:00

Break

11:30 - 12:00

Room 1

Coffee Break*Clinical*

12:00 - 13:30

Room 1

Scientific Session 16: Cognition*Chair:* Dawn Langdon, GB*Chair:* Ralph Benedict, US

Introduction by chairs	12:00 - 12:05
Aging in MS and cognition	12:05 - 12:20
<i>Speaker:</i> Maria Pia Amato, IT	
Prevention versus treatment	12:20 - 12:35
<i>Speaker:</i> Hanneke Hulst, NL	
Platform presentations of related original papers	12:35 - 12:35
Discussion	12:35 - 13:02

Imaging and non-imaging biomarkers/Translational

12:00 - 13:30

Room 2

Scientific Session 17: Blood based biomarkers: when to implement?*Chair:* Eline Willemse, CH*Chair:* Fredrik Piehl, SE

Introduction by chairs	12:00 - 12:05
NfL use in clinical practice: normal reference values	12:05 - 12:20
<i>Speaker:</i> Michael Khalil, AT	
NfL use in clinical trials: prognostic and outcome measure	12:20 - 12:35
<i>Speaker:</i> Robert J. Fox, US	

	Platform presentations of related original papers	12:35 - 12:35
	Discussion	12:35 - 13:02
12:00 - 13:30		Room 3
	ECTRIMS-EAN Session	
	<i>Chair:</i> Bruno Stankoff, FR	
	<i>Chair:</i> Paolo A. Muraro, GB	
	Introduction by chairs to the ECTRIMS Focused Workshop on HSCT and MS	12:00 - 12:05
	Efficacy of HSCT: clinical evidence in relapsing and progressive MS patients	12:05 - 12:15
	<i>Speaker:</i> Gian Luigi Mancardi, IT	
	When should HSCT be considered in the sequence of possible disease modifying therapies?	12:15 - 12:25
	<i>Speaker:</i> Basil Sharrack, GB	
	Defining the Conditioning regimens and Transplant protocols	12:25 - 12:35
	<i>Speaker:</i> Riccardo Saccardi, IT	
	Neurological follow up and management of disease reactivation following HSCT	12:35 - 12:45
	<i>Speaker:</i> Ellen Iacobaeus, SE	
	Infections and autoimmunity in the context of HSCT : prevention and management	12:45 - 12:55
	Discussion	12:55 - 13:10
<i>Therapy / Global views</i>		
12:00 - 13:00		Room 4
	Hot Topic 9: Pharmacovigilance	
	<i>Chair:</i> Jorge Correale, AR	
	<i>Chair:</i> Bruce A. Cree, US	
	Introduction by chairs	12:00 - 12:05
	Long term safety in DMT use	12:05 - 12:15
	<i>Speaker:</i> Renaud Du Pasquier, CH	
	Early recognition of CNS complications	12:15 - 12:25
	<i>Speaker:</i> Mike P. Wattjes, DE	
	How to manage CNS complications	12:25 - 12:35
	Discussion	12:35 - 13:00

Pathogenesis

12:00 - 13:00

Room 5

Hot Topic 10: Emerging role of lipids in MS*Chair:* Valbona Mirakaj, DE*Chair:* Gijs Kooij, NL**Introduction by chairs**

12:00 - 12:05

Lipid metabolism in macrophages directs lesion progression and repair in MS

12:05 - 12:15

Speaker: Jerome JA Hendriks, BE**Oleic acid and restoring Treg function**

12:15 - 12:25

Speaker: David A. Hafler, US**Cell-type-specific sterol synthesis**

12:25 - 12:35

Speaker: Gesine Saher, DE**Discussion**

12:35 - 13:00

Clinical

12:00 - 13:00

Room 6

Meet the Expert 4: Preventing misdiagnosis*Chair:* Matilde Inglese, IT*Chair:* Jeffrey Cohen, US*Educational Sessions*

12:00 - 13:00

Room 7

Educational Session 21: Treatment of progressive MS*Chair:* Ludwig Kappos, CH*Chair:* Benedetta Bodini, FR**Introduction by chairs**

12:00 - 12:05

Should secondary progressive patients be treated with an S1PR modulator or an anti-CD20 treatment?

12:05 - 12:20

Speaker: Ludwig Kappos, CH**Can progressive patients be monitored by MRI?**

12:20 - 12:35

Speaker: Benedetta Bodini, FR**Do current treatment options exert a direct neuroprotective effect?**

12:35 - 12:50

Speaker: Jeremy Chataway, GB**Discussion**

12:50 - 13:00

Educational Sessions

12:00 - 13:00

Room 8

Educational Session 22: Beyond MS - paraneoplastic syndromes, iatrogenic demyelination and autoimmune encephalitis*Chair:* Amy Kunchok, US**Introduction by chairs**

12:00 - 12:05

A practical update: Diagnosis and management of paraneoplastic neurological syndromes	12:05 - 12:20
<i>Speaker:</i> Maarten Titulaer, NL	
CNS inflammation complicating immunotherapies: A rising spectrum	12:20 - 12:35
<i>Speaker:</i> Amy Kunchok, US	
Autoimmune encephalitis	12:35 - 12:50
Discussion	12:50 - 13:00
<i>Break</i>	
13:30 - 14:15	Room 1
Lunch Break	
<i>Satellite Symposium</i>	
14:15 - 15:15	Room 1
Satellite Symposium 11	
<i>Satellite Symposium</i>	
14:15 - 15:15	Room 2
Satellite Symposium 12	
<i>Late Breaking Abstracts</i>	
15:30 - 16:30	Room 1
Scientific Session 18: Late Breaking Abstracts	
<i>Chair:</i> Mar Tintoré, ES	
<i>Chair:</i> Tobias Derfuss, CH	
<i>Break</i>	
16:30 - 17:00	Room 1
Coffee Break	
<i>Plenary Sessions</i>	
17:00 - 18:00	Room 1
Plenary Session 2: Awards, ECTRIMS Honorary Members, Confavreux Lecture and ECTRIMS 2022 Highlights	
<i>Chair:</i> Maria Pia Amato, IT	
<i>Chair:</i> Mar Tintoré, ES	
<i>Chair:</i> Bernard Uitdehaag, NL	
Introduction by chairs	17:00 - 17:05
Presentation of ECTRIMS Awards, RIMS Awards, MSIF Award and ECTRIMS-ECF Award as well announcement of ECTRIMS Honorary Members	17:05 - 17:15
Confavreux Lecture: The future of neuropathology in MS	17:15 - 17:35
<i>Speaker:</i> Christine Stadelmann-Nessler, DE	
Clinical highlights	17:35 - 17:45

Speaker: Celia Oreja-Guevara, ES

Speaker: Heinz Wiendl, DE

Scientific highlights

17:45 - 17:55

Speaker: Elga de Vries, NL

Speaker: Gianvito Martino, IT

Welcome to ECTRIMS 2023

17:55 - 18:00